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Background: Myeloid derived suppressor cells (MDSCs) are a recently described population of immune cells that
significantly contribute to the immunosuppression seen in cancer patients. MDSCs are one of the most important
factors that limit the efficacy of cancer immunotherapy (e.g. cancer vaccines) and MDSC levels are increased in
cancer in multiple species. Identifying and targeting MDSCs is actively being investigated in the field of human
oncology and is increasingly being investigated in veterinary oncology. The treatment of canine cancer not only
benefits dogs, but is being used for translational studies evaluating and modifcying candidate therapies for use in
humans. Thus, it is necessary to understand the immune alterations seen in canine cancer patients which, to date,
have been relatively limited. This study investigates the use of commercially available canine antibodies to detect
an immunosuppressive (CD11blow/CADO48low) cell population that is increased in the peripheral blood of
tumor-bearing dogs.
Results: Commercially available canine antibodies CD11b and CADO48A were used to evaluate white blood cells
from the peripheral blood cells of forty healthy control dogs and forty untreated, tumor-bearing dogs.
Tumor-bearing dogs had a statistically significant increase in CD11blow/CADO48Alow cells (7.9%) as compared to the
control dogs (3.6%). Additionally, sorted CD11blow/CADO48Alow generated in vitro suppressed the proliferation of
canine lymphocytes.
Conclusions: The purpose of this study was aimed at identifying potential canine specific markers for identifying
MDSCs in the peripheral blood circulation of dogs. This study demonstrates an increase in a unique CD11blow/
CADO48Alow cell population in tumor-bearing dogs. This immunophenotype is consistent with described
phenotypes of MDSCs in other species (i.e. mice) and utilizes commercially available canine-specific antibodies.
Importantly, CD11blow/CADO48Alow from a tumor environment suppress the proliferation of lymphocytes. These
results provide a useful phenotype of cells increased in canine cancer patients that may serve as a useful prognostic
marker for assessing immune status and functional response to cancer immunotherapies in dogs. Understanding
MDSCs in dogs will allow for increased effectiveness of cancer immunotherapy in both dogs and humans.
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Myeloid derived suppressor cells (MDSC) are immature
myeloid cells produced by bone marrow precursor cells
that are increased in a variety of diseases. Most signifi-
cantly, MDSCs are increased in cancer patients and sig-
nificantly contribute to the immunosuppression of these
cancer patients [1]. MDSCs are immature myeloid cells
which are arrested during differentiation (myelopoiesis)* Correspondence: papenfuss.1@osu.edu
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reproduction in any medium, provided the orand accumulate [2,3]. Utilizing the immune system to
specifically target the destruction of cancer cells (i.e.
cancer immunotherapy) is conceptually appealing but
has proven to be difficult therapeutically. The efficacy
of cancer vaccines has proven relatively unsuccessful in
patient populations due, in large part, to the dysregulated
immune system of cancer patients. MDSCs are signifi-
cant contributors to the immunosuppression in cancer.
Although suppressive myeloid cells were recognized over
forty years ago, the understanding that MDSCs con-
tribute to the immunosuppression that limits cancerl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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immunosuppressive myeloid cells [4-6].
MDSCs are a heterogeneous population of cells with
a variety of phenotypic markers being recognized which
have variably been used to identify subsets. By and
large, MDSCs are identified as CD11b+Gr1+ in mice
and CD33+HLA–DR–Lin– in humans although numerous
additional markers (e.g. S100A, etc.) have been used to
categorize MDSC subsets. The dual expression of CD11b
(myeloid marker) and Gr1 (granulocytic marker) high-
lights the immature nature of these cells and the fact
that these cells arise from a common myeloid precursor
that differentiates into dendritic cells (DCs), macrophages
and granulocytes. Although present normally at low levels,
under pathologic conditions, elevated numbers of these
cells are found in both the peripheral circulation and
lymphoid organs [7]. The accumulation of MDSCs is
thought to be due to a variety of factors including a wide
array of soluble factors produced from the tumor envir-
onment (e.g. GM-CSF, VEGF, IL-1beta, IL-6, S100A8/A9,
etc.). A variety of therapies aimed at limiting MDSC
actions have been used to prevent the formation of
MDSCs (e.g. tyrosine kinase inhibitors, Sunitinib), reduce
MDSC accumulation (e.g. gemcitabine, 5-fluorouracil),
affect MDSCs inhibitory abilities (e.g. phosphodiesterase
5 inhibitors, nitroaspirin) or promote MDSC differenti-
ation (e.g. retinoic acid and vitamin D) [1,8-14].
MDSCs suppress both innate and adaptive immune
responses through a combination of cell contact-mediated
mechanisms (e.g. expression of inhibitory surface marker
PD-L1) and the production of a wide array of soluble
mediators (e.g. arginase, nitric oxide and reactive oxygen
species) [15,16]. Cells which have been shown to be inhib-
ited by MDSCs include natural killer (NK) cells, macro-
phages, DCs, CD4+ helper T cells, CD8+ (cytotoxic) T cells
and NK-T cells. Additionally, MDSCs are recognized to
promote regulatory T (Treg) cell production where Tregs
are potently immunosuppressive in their own right [17].
Through these multiple actions, MDSCs significantly con-
tribute to the immune dysregulation and immunosuppres-
sion seen during cancer and are important roadblocks to
achieving complete anti-tumor immunity.
Assessment of MDSC levels in cancer patients may pro-
vide an important means to evaluate not only relative im-
mune status, but also may be useful biomarkers to evaluate
response to therapy. For that reason, easy, rapid and accur-
ate identification of MDSCs is critical. CD11b+Gr1+ cells
are useful markers used to identify MDSCs in mice
and studies have demonstrated specific monocytic
(Ly6ChiLy6G+) and granulocytic (Ly6ClowLy6G+) subsets
that may be distinctly contribute to the immunosuppres-
sion present in cancer [1,18,19]. Similarly, in humans, the
CD33+HLA–DR–Lin– MDSC population can be categor-
ized into subpopulations but the contribution of specificsubsets to disease pathogenesis is less well defined than
in mouse models. The relative identification of MDSCs
in other species remains relatively undescribed but has
important therapeutic applications in both veterinary and
human oncology.
Increasingly, the dog is being used as both a large
animal model for carcinogenesis studies and the assess-
ment of cancer therapies due to the similarities between
dogs and humans (e.g. outbred population, shared envir-
onmental exposures, etc.). Additionally, dog owners are
increasingly interested in state-of-the-art therapeutics and
are receptive to enrolling their dogs into clinical trials for
experimental therapeutics. Thus, there are increasing op-
portunities not only to assess the responsiveness of canine
cancer patients to particular novel therapeutics and cancer
immunotherapy, but to apply the acquired information
(e.g. drug pharmacokinetics, pharmacodynamics, dos-
ing regimens and efficacy) for clinical applications in
human cancer patients. At present, the use of cancer im-
munotherapy is relatively limited in veterinary medicine
but the approval and clinical application of immunother-
apies such as the canine melanoma vaccine and Palladia
for canine mast cells are reflective of an increased interest
in this useful therapeutic approach [9,20. Given these
facts, it becomes necessary to understand the immune
alterations seen in cancer patients which, to date, have
been relatively limited [21,22]. The accurate identification
and assessment of MDSC levels in dogs is important to
understand the contribution of these potent immunosup-
pressive cells in canine cancer. Additionally, the identifica-
tion of an MDSC phenotype provides a means to assess
peripheral blood MDSCs which may serve as a useful
prognostic marker for assessing immune status and func-
tional response to cancer immunotherapies. This study
identified canine specific markers that can be used to
identify specific myeloid cell populations within clinical
samples from dogs. Our data demonstrate that canine-
specific antibodies can be used to identify a specific popu-
lation of myeloid cells (CD11blowCADO48Alow) which are
increased in tumor-bearing canine patients and that
purified CD11blowCADO48Alow cells suppressed the pro-
liferation of canine lymphocytes.
Methods
Study Design/Animals
Eighty client-owned dogs were prospectively enrolled in the
study at The Ohio State University’s Veterinary Medical
Center. Forty dogs presenting to the Community
Practice or Blood Bank Services without evidence or his-
tory of neoplasia were enrolled into the control group.
Forty dogs presenting to the Medical or Radiation
Oncology Services were enrolled into the experimental
population. Inclusion criteria for patients in the experi-
mental population were (1) cytological or histopatholgic
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local or metastatic disease, (3) no prior surgical of che-
motherapeutic treatment and (4) no prior history of neo-
plasia. No patients with round cell tumors were enrolled
in the study. Animal use was approved by The Ohio
State University’s Institutional Animal Care and Use
Committee and The Ohio State University’s Veterinary
Medical Center’s Clinical Research Advisory Committee.
Flow Cytometry Staining and Optimization
Initial studies optimized the application of commercially
available antibodies for detection of MDSCs in dogs.
Whole blood samples were obtained through peripheral
venipuncture from dogs using approved Institutional
Animal Care and Use Committee (IACUC) protocols.
The concentration of antibodies and the relative influ-
ence of sample handling and influence of time and fix-
ation after staining were evaluated (Figure 1). Briefly,
erythrocytes were removed from whole blood samples
using erythrocyte lysis buffer (NH4Cl/KHCO3/EDTA),
washed with 1x PBC, resuspended in fluorescence-
activated cell sorting buffer (FACS; PBS containing
0.1% BSA and 0.1% sodium azide) and placed into
flow tubes at a final concentration of 5x105/100uL. Cells
were then stained with a panel of antibodies including
MHC class II (AbdSerotec, MCA1044F; clone YKIX334.2),
IgG1 (AbdSerotec, MCA928), CD11b (AbdSerotec,
MCA1777S; clone CA16.3E10), CD14 (AbdSerotec,
MCA1568A647; clone TUK4), DH59B (previously
VMRD, now Monoclonal Antibody Center, Washington
State University; clone DH59B), CADO48A (Monoclonal
Antibody Center, Washington State University; clone
CADO48A) and available isotype controls. All antibodies
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Figure 1 Staining characteristics and evaluation of two commercially
blood. (a) Cells were analyzed according to forward and side scatter. Cells
including lymphocytes (R1, lymphocytes are circled) and all myeloid cells (P
CADO48A or (b) DH59B with the same concentration of secondary antibod
additional cell population as compared to DH59B (b). These results were re
(b) were gated on P1 as indicated in (a).MHC class II and CD14 which were directly conjugated
to fluorescein isothiocyanate (FITC) and Alexa Fluor
647 (BD Biosciences), respectively. Secondary antibodies
of either phycoerythrin (PE; 5 uL) or Fluorescein iso-
thiocyanate (FITC; 1uL) both from AbD Serotec were
used to stain CD11b, CADO48A and DH59B at various
dilutions (1:10, 1:50, and 1:100) for optimization stud-
ies. Results from these optimization studies were then
used on the clinical patient samples. Samples were run
on an BD Accuri flow cytometer and analyzed with BD
Accuri CFlow analysis software. Samples were run im-
mediately following staining or fixed in 4% formalin
for 4, 24 and 48 hours after staining for optimization
(Figure 2) and immediately upon preparation for clin-
ical patient blood samples.
Flow Cytometry of patient samples
Upon blood collection (EDTA tube), the sample was
kept at 4°C before staining and all samples were pro-
cessed within 12 hours of collection. Each patient sam-
ple was divided into sample evaluation of 1) cells alone
(no antibody), 2) MHC class II, 3) IgG1, 4) CD11b, 5)
CADO48A and 6) a combination of CD11b and
CADO48A (Figure 3) using antibody concentrations
determined during the optimization protocols. The pri-
mary antibodies CD11b and CADO were secondarily
stained with 5uL PE and 1 uL of a 1:50 dilution of FITC
respectively. As previously described, samples were pre-
pared and analyzed with the BD Accuri flow cytometer.
Data analysis of specific blood cell populations was per-
formed. Specifically, cells were evaluated based on 1)
all cells (both dead and live cells, ungated), 2) all per-
ipheral blood mononuclear cells (PBMC) or R1, and





available canine granulocytic antibodies of canine peripheral
were either gated to include all live and dead (no gate), all live cells
1). (b) Cells were labeled using canine anti-CD11b and either (a)
y FITC. As can be seen in (a), CADO48A allows visualization of an
peatable with multiple blood samples from different dogs. The cells in













Figure 2 Optimization of secondary antibody staining concentration for detection of CADO48A. Cells were stained with the primary
antibody CADO48A alone followed by (a) 1:10 (b) 1:50 and (c) 1:100 dilutions of a secondary FITC antibody. Optimal detection was seen between
1:50 and 1:100 dilution with CADO48A alone. Secondary FITC concentrations of 1:50 (d) and 1:100 (e) to detect CADO48A on pre-labeled CD11b
cells were then evaluated and demonstrated that a 1:50 concentration of FITC was optimal for optimal detection of distinct CADO48A+ cells.
Based on these findings, a 1:50 FITC concentration was used in all clinical samples. All cells in these diagrams were gated on P1.
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or P1. Direct CD11b+CADO48A+ staining on these
cell populations was assessed (Figure 4). Subsequent
gates were assigned as follows P2 (CD11bhiCADOhi),
P3 (CD11bhiCADOlow) and P4 (CD11blowCADOlow)
(Figure 5). For all gates, the percent and total count of all
cells staining positive for both antibodies was determined.
In vitro differentiation, proliferation assay and cytospin of
canine MDSCs
Canine bone marrow was approved from humanely
euthanized dogs on an approved IACUC protocol. Bone
marrow was differentiated in the presence of 10 ng/ml
human GM-CSF (or 20 ng/ml canine GM-CSF) for
4–5 days with or without 20% tumor-conditioned media
from a canine-specific melanoma MEL-16 line (kindly
provided by Dr. Cheryl London). Cells were then labeledas described above for CD11b and CADO48A and sorted
using a FACSAris flow sorter. Purified cells were then
co-cultured at a 1:5 ratio with responder canine spleno-
cytes and stimulated for 40 hours with 1 ug/ml LPS
(Sigma) or 3 ug/ml conA (Sigma) with a final pulse of
3 H thymidine in the last 18 hours of culture. An ali-
quot of cells was prepared by cytospin (1500 rpm for
5 minutes), stained with Wright-Giemsa and photomi-
crographs taken at a 60x magnification.
Statistical Analysis
For all statistical analyses, the percentage of cells stain-
ing positive for both CADO48A and CD11b were evalu-
ated. Differences between the control and experimental
groups were compared using a Wilcoxon rank-sum
(Mann–Whitney) test. Additional comparisons between
the individual tumor types (sarcoma, carcinoma and










































Figure 3 Effects of EDTA versus media storage of patient blood samples on flow cytometric results. Peripheral blood cells were
(a) stained immediate following collection with CD11b and CADO48A or maintained in EDTA collection tubes for (b) 24 or (c) 48 hours or in
media for (d) 24 or (e) 48 hours prior to staining with CD11b and CADO48A. Both EDTA and media samples were kept refrigerated. These
findings show a decrease over time of population distinction in EDTA with minimal changes when cells are kept in media up to 48 hours. All
cells were gated on P1.
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of-populations rank test. For all comparisons made,
p-values less than 0.05 were considered to be significant.
Results
Flow Cytometry Optimization
Canine blood samples evaluated by forward scatter (FSC)
and side scatter (SSC) (Figure 1) demonstrated distinct
populations of small non-granular cells (i.e. lymphocytes)
and large granular cells (P1). Based on size and granular-
ity, large granular cells present within the P1 gate were
evaluated for expression of cell surface markers of
CD11b and commercially available canine granulocyte
markers CADO48A and DH59B. Figure 1b demonstrates
an increased distinction in cell subpopulations evidence
with CADO48A staining that was not apparent with
DH59B staining. Based on these results, we chose to
utilize CADO48A in identifying potential canine MDSCs
and myeloid cell populations in canine peripheral blood
samples. We first optimized the secondary antibodyconcentration to detect double positive CD11b and
CADO48A. Previous work (data not shown) showed that
a 1:50 dilution for secondary antibody staining of CD11b
effective identifies CD11b+ cells in canine peripheral
blood. We next evaluated specific dilutions of secondary
FITC antibody staining for detection of CADO48A.
Figure 2 shows that a optimal detection was seen at a
concentration between 1:50 and 1:100 secondary FITC
antibody both in single-labeled CADO48A+ cells and
in cells that were dual-labeled with CD11b on PE and
CADO48A on FITC. Based on these findings, a 1:50 FITC
concentration was used in all clinical samples. All cells in
these diagrams were gated on P1.
Given the variable nature of procurement, handling
and processing of clinical samples, we next evaluated the
influence of sample handling, timing of antibody labeling
and fixation of samples. Figure 3 shows the results of
evaluating the effect of immediate staining of cells after
collection or staining after storage in either EDTA or 5%
RPMI culture media for 24 or 48 hours. Cells that
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Figure 4 Effections of fixation on CD11b and CADO48A expression levels. Cells were stained for CD11b and CADO48A and evaluated
pre-fixation (a) or subsequently fixed with 4% paraformaldehyde at (b) 4 hours, (c) 24 hours), (d) 48 hours or (e) 72 hours post-fixation before
analysis on the flow cytometer. Fixation of cells appears to have limited effects on expression levels of CD11b and CADO48A expression up to
24 hours and then only mild increases of 4-6% of CD11b+CADO48A+ cells are seen at 24, 48 and 72 hours post-fixation. All cells seen in this

















Figure 5 Gated myeloid subpopulations evaluated for patient population. All peripheral blood myeloid cells were evaluated using the
P1 gate (non-lymphocytes) and subsequently gated based on relatively expression levels of CD11b and CADO48A where CADO48Ahi/CD11bhi
(gate P2), CADO48Alow/CD11bhi (gate P3) and CADO48Alow/CD11blow (gate P4) likely represent granulocytes/neutrophils, monocytes and MDSCs,
respectively.
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Table 1 Description of patient characteristics for the
control and experimental groups
Control



























Patient characteristics at the time of study enrollment are described.
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strated the most consistent results compared to those
stored in EDTA or media for 24 hours. While cells stored
in media demonstrated no change in CD11b/CADO48A
expression after 48 hours, there was a slight decrease in
CD11b+CADO48A+ cells in cells stored in EDTA for
48 hours. In general, the entire population of cells in
48 hour EDTA-treated cells had diminished CADO48A
expression which contributed to the decreased in double
positive cells. These findings suggest that media storage of
samples for up to 48 hours can provide consistent and
similar results to samples processed immediately for eval-
uated CD11b/CADO48A expression while storage of sam-
ples in EDTA for more than 24 hours may alter the
receptor expression of cells. For all subsequent blood sam-
ple evaluation, samples were processed immediately unless
otherwise indicated.
Fixation of cells with 4% paraformaldehyde following
staining with flow antibodies demonstrated that the
expression levels of CD11b and CADO48A remain rela-
tively constant over time with no change evident in the
percentage of CD11b+CADO48A+ cells seen even after
72 hours (Figure 4). While immediate evaluation of clin-
ical samples for the expression levels of cell surface mar-
kers is ideal, our results suggest that samples can be
stored for up to 24 hours in EDTA or 48 hours in media
and that cells can be fixed following antibody staining
and analyzed up to 72 hours later without dramatically
impacting the expression of CD11b+CADO48+ levels.
Clinical Patient Blood MDSC Evaluation
Following the optimization studies, we next evaluated
the patient populations of both tumor-bearing and con-
trol dogs for the presence of MDSCs. A total of 80
patients were enrolled into the study between April 2011
and January 2012. The control group was comprised of
40 dogs with a median age of 5.0 years (range 3–
15 years) and a variety of breeds represented as outlined
in Table 1. The experimental tumor-bearing group was
comprised of 40 dogs with a median age of 9.3 years
(range 3–14 years) with represented breeds and various
tumor types (sarcomas; n=19), carcinomas; n=18) and
oral melanomas; n=3) represented (Table 1). The relative
expression levels of CD11b and granulocytic markers,
such as CADO48A, have been used to identify specific
populations of MDSCs. Based on differing levels of both
CD11b and CADO48A expression in CD11b+CADO48A+
cells we found 3 distinct cell populations (P2-P4) that
are shown in Figure 6. These cells were CADO48Ahi/
CD11bhi (P2), CADO48Alow/CD11bhi (P3) and
CADO48Alow/CD11blow (P4) and, based on staining
characteristics of CD11b and granulocytic marker expres-
sion, are most consistent with a neutrophil, monocyte and
myeloid precursor (i.e. putative MDSC) population,respectively. To determine whether specific myeloid cell
populations are increased in tumor-bearing dogs, we
next evaluated the levels of P2, P3 and P4 in tumor-
bearing versus control dogs. Table 2 demonstrates the
percentage of positive cells and associated statistical
parameters (e.g. mean, median, SD, min, max) for both
CD11b and CADO48A in control and tumor-bearing
dogs. While no significant differences were seen in either
P2 or P3, a statistically significant increase in CD11blow/
CADO48Alow population (i.e. P4 gate) was seen (p<0.048)
in tumor-bearing dogs (Table 2, Figure 7). These results
show that a CD11blow/CADO48Alow myeloid precursor
population was increased in tumor-bearing dogs. We next
determined whether tumor-type influenced the levels of
CD11blow/CADO48Alow cells. Table 3 demonstrates the
percentage of CD11b+CADO48A+ cell populations when






















Figure 6 Increased percentage of CD11blow/CADO48Alow in tumor-bearing canine patients. The expression levels of CD11blow and
CADO48Alow was evaluated from the peripheral blood of representative canine patients and show an increase of CD11blow/CADO48low in
tumor-bearing canine patients.
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across individual tumor types (i.e. sarcoma, carcinoma
and melanoma). Table 3 shows an increased percent-
age of CD11b+CADO48A+ cells in both all live cells
(i.e. R1 gate, p=0.027) and in the myeloid non-
lymphocytes (i.e. P1 gate, p=0.036). When comparing
across tumor types compared to controls with melanoma-
bearing dogs demonstrating the highest levels of R1
and P1. However, an increase in P4 was not consist-
ently evident when samples were grouped on individ-
ual tumor-types. Figure 6 demonstrates representative
plots of CD11b/CADO48A expression in control dogs
and dogs with differing tumor types. Taken together,
these data demonstrate that CADO48Alow/CD11blow
cells were increased in tumor-bearing dogs and that
melanoma-bearing dogs demonstrate the highest levels of
CD11b+CADO48A+ cells compared to either sarcomas
or carcinomas.Suppressive abilities of CD11blow/CADO48Alow cells
We next wanted to determine whether the increase in
CD11blow/CADO48Alow cells present in tumor-bearing
dogs could impact immune function. To do this, we gener-
ated CD11blow/CADO48Alow cells and assessed their ability
to suppress the proliferation of responder canine immune
cells. To generate sufficient numbers of CD11blow/
CADO48Alow cells for functional evaluation, we utilized an
in vitro system to differentiate canine MDSCs and control
myeloid precursor cells from bone marrow myeloid pro-
genitors. Sorted CD11blow/CADO48Alow cells were able to
suppress the proliferation of responder canine splenocytes
following conA stimulation but not in LPS-stimulated cells
(Figure 7). Cellular morphology was relatively similar
between control and melanoma myeloid precursors
although overall expression levels of both CD11b and
CADO48A was slightly decreased in the myeloid cells
exposed to melanoma tumor-conditioned media which
Table 2 Comparison of percent of cells positive for
CD11b/CADO48A by gate of control and tumor-bearing
dogs
Control Mean Median Min Max
Ungated 31.9±14.4 27.2 12.6 58.2
R1 28.4±10.3 24.4 10.9 50.6
P1 27.5±10.1 23.6 10.6 49.0
P2 24.2±09.2 20.8 8.6 45.3
P3 4.6±2.8 4.0 1.5 13.4
P4 3.6±1.7* 3.0 1.3 7.7
Tumor
Ungated 33.7±15.0 29.3 11.4 72.3
R1 30.0±14.1 26.9 8.5 66.9
P1 29.1±14.0 26.0 7.2 65.2
P2 25.5±12.8 22.5 8.1 59.6
P3 4.5±3.6 3.5 1.2 20.3
P4 7.9±3.0* 3.7 1.1 12.7
The percentage of cells staining positive for CD11b and CADO48A are
displayed for each gate analyzed for both the control and tumor-bearing
populations. Cells from the P4 gate of the tumor bearing dogs were found to
be elevated as compared to the healthy control dogs. No other statistical
differences were seen in the other gates analyzed. An * denotes statistical
significance (P<0.05). All values are expressed as a percentage of all cells
analyzed by flow cytometry.
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described for MDSCs. Taken together, these results
show that CD11blow/CADO48Alow cells were func-

























Figure 7 Purified CD11blowCADO48Alow cells from in vitro differentiat
lymphocytes. Bone marrow cells were differentiated in either GM-CSF (Media)
Cells were purified and co-cultured at a 1:5 ratio with responder canine splenoc
cells shows a mixed population of myeloid and granulocytic precursor cells dem
the CD11blow/CADO48Alow populations of both media and melanoma cells. PhDiscussion
This study investigated potential canine-specific markers
for identifying MDSCs in the peripheral blood of dogs
with cancer. We began our studies by first identifying
potential phenotypic markers that could be used for
identifying canine MDSCs. Prototypic MDSC phenotypic
markers have been reported as CD11b+/CD33+/HLDRlow
in humans and CD11b+/Gr-1+ in mice [1]. In humans,
CD15 (granulocytic) and CD14 (monocytic) identify subpo-
pulations of these cells while, in mice, CD11b+Ly6G+ and
CD11b+Ly6C+ cells identify these cells as either granulo-
cytic or monocytic, respectively. Unfortunately, the lack of
readily available commercial canine antibodies has limited
the identification of MDSCs and MDSC subsets in dogs.
CD11b, an integrin, is found on a variety of cells of
myeloid origin and has been used as one phenotypic
marker of MDSCs present in the mouse and man. In the
dog, CD11b in known to be a marker of cells of myeloid
origin, most specifically neutrophils [23]. There is a com-
mercially available anti-canine CD11b available which
has been validated. In the mouse, Gr-1 is a granulocytic
marker whose co-expression with CD11b is used to iden-
tify the immature myeloid cell population that represents
MDSCs. Although CD11b is useful to identify myeloid
(e.g. macrophages/DCs), neutrophils and mast cells in the
dog, no Gr-1 equivalent for the dog has been described.
Additionally, murine Gr-1 has demonstrated a variable
ability to stain canine cells, and its individual compo-






ed myeloid cells suppressed the proliferation of T and B
or GM-CSF with canine melanoma tumor-conditioned media for 5 days.
ytes and the (a) proliferation of cells determined. A cytospin (b) of purified
onstrating monocytic, granulocytic and ring-shaped nuclei are present in
otomicrograph of the cytospin is at 60x magnification.
Table 3 Comparison of percent of cells positive for
CD11b/CADO48A by gate amongst tumor types
Sarcoma Mean Median Min Max
Ungated 33.4±12.7 28.7 13.5 58.2
R1 29.9±12.5* 26.5 11.7 53.1
P1 29.0±12.6* 25.5 11.6 51.8
P2 25.1±12.0 22.4 8.2 50.6
P3 4.8±4.7 3.5 1.6 20.3
P4 4.7±2.9 3.8 1.1 12.6
Carcinoma
Ungated 30.4±14.8 23.8 11.4 64.5
R1 26.4±12.8* 21.5 8.5 55.6
P1 25.3±12.5* 21.0 7.2 53.6
P2 22.7±11.4 18.2 8.1 47.9
P3 3.7±1.9 3.1 1.2 8.0
P4 5.1±3.5 3.5 2.1 12.7
Melanoma
Ungated 56.0±15.2 53.5 42.3 72.3
R1 52.6±13.5* 51.0 40.0 66.9
P1 51.6±13.0* 50.2 39.3 65.2
P2 44.7±13.5 41.2 33.3 59.6
P3 7.8±2.2 7.7 5.7 10.1
P4 4.8±1.1 4.5 3.8 6.0
The percentage of cells staining positive for CD11b and CADO48A are
displayed for each tumor subtype: sarcoma (n= 19), carcinoma (n=18) and
melanoma (n=3). Patients were categorized into one of the three groups
based on either cytology or histopathology. A statistical difference was seen in
the R1 and P1 gates between the 3 tumor types on initial analysis. When the
melanoma patients were excluded due to low patient numbers no statistical
difference was seen in the percent of CD11b/CADO48A positive cells, in any
gate, between the sarcoma or carcinoma patients. An * denoted statistical
significance (p<0.05). All values are expressed as a percentage of all cells
analyzed by flow cytometry.
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Rather, CD33, CD14 and HLA-DR (i.e. MHC class II)
expression are used to specifically identify these cells.
No canine specific, or cross-reacting, CD33 antibody is
currently commercially available. Although human CD14
cross-reactive with canine cells, canine CD14 expression
is variable on monocytes and likely may not truly mimic
what is seen in humans [26]. Additionally, standardized
protocols and antibody concentrations using CD14 in
the canine have not been established [27]. However, a
recent publication by Goulart et al. has demonstrated
the use of negative labeling for CD14 expression to iden-
tify an MDSC population in the dog but no studies have
investigated canine-specific granulocytic antibodies to
identify an MDSCs in the dog [21]. Considering the lack
of anti-canine CD33 and human MDSC subpopulations
express markers which are not commercially available
(e.g. canine-specific CD15 or CD14), we chose to evaluate
the levels of canine-specific CD11b and a granulocyticmarker which models the phenotypic description for
murine MDSCs.
Only two commercially available markers are reported
to label canine granulocytes (i.e. CADO48A and DH59A)
and our results show that CADO48A is able to dis-
tinguish separate populations that are not evident in
DH59A stained populations from canine peripheral
blood. While our focus was on canine-specific antibodies,
we did evaluate the cross-reactivity of murine Gr-1 with
canine peripheral blood samples. Murine Gr-1 (clone
RB6-8C5) failed to stain canine peripheral blood cells,
results which differ from the ability of this clone to stain
canine cells by Goulart et al. [21]. Our studies suggest
that canine-specific CADO48A is an effective antibody
to identify circulating myeloid cells in canine blood.
The ability of CADO48A to identify individual granulo-
cytic populations of peripheral white blood cells (high
versus low expression) as seen in Figure 1 suggests that
this antibody may be useful for identifying granulocytic
versus monocytic subpopulation but purification and
functional evaluation of such subpopulations were beyond
the scope of this study. Our results demonstrate that
CD11b and CADO48 staining is useful for detecting
subpopulations of myeloid cells in the peripheral blood
of dogs. From our optimization studies, we found that
clinical samples can be stored up to 24 hours in EDTA,
48 hours in media and that cells that have been fixed
following staining with flow antibodies can be analyzed
up to 72 hours later without dramatically impacting
the expression of CD11b+CADO48+ levels. From a diag-
nostic standpoint, it is important to know the relative
expression levels of these markers depending on sample
treatment and handling.
Following optimization, we next went on to determine
whether tumor-bearing dogs demonstrated altered levels
of myeloid cell populations. Our results show that a
specific population of CD11blowCADO48Alow cells was
increased in tumor-bearing dogs. The finding of an
upregulated population of cells in tumor-bearing dogs
expressing CD11b, as well as, the surrogate marker
CADO48A, is suggestive of an MDSC phenotype in the
canine. Classically, MDSC expression of CD11b is con-
sidered to be high. In our canine samples, we found that
the expression in the canine patient to be low. While this
finding is discordant from the literature on MDSCs in
the mouse and human, CD11b expression is known to be
variable both in healthy people at different time points
and in animals with varying severity of inflammation
[28,29]. Additionally, it has been shown in human cell
lines that during neutrophil maturation from a promye-
locytic stage of development to a more terminally dif-
ferentiated state CD11b expression starts low and
eventually reaches high levels of expression once fully
mature [30]. If the cells in our tumor-bearing dogs
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expression may be representative of MDSCs. Additionally,
work done by Furuhashi et al. has shown that DCs with
high CD11b expression are more capable of eliciting a
T-cell response in the pulmonary parenchyma of mice,
indicating that increased CD11b expression is a relative
marker of increased maturation and/or activation of DCs
[31]. Based on our results and previously published find-
ings, low CD11b expression may in fact be indicative of
an early myeloid derived cell population such as MDSC.
Additionally, the cellular morphology of our purified
CD11blowCADO48Alow cells is consistent with an imma-
ture and heterogeneous cellular morphology described for
MDSC populations [1,18,19] in mice which contain cells
demonstrating monocytic, granulocytic and ring-shaped
nuclear forms (Figure 7B). Thus, we postulated that
CD11blowCADO48Alow represent an MDSC population.
In order to determine whether, indeed, CD11blow
CADO48Alow were immunosuppressive, we utilized our
in vitro model to generate canine MDSCs under the in-
fluence of a tumor environment and purified the
CD11blowCADO48Alow population. As Figure 7 demon-
strates, CD11blowCADO48Alow were able to suppress
the proliferation of responder canine lymphocytes.
While cell sorting and functional evaluation of indi-
vidual cancer patients were beyond the scope of this
study, our data from purified CD11blowCADO48Alow
(from control or tumor environment) verified that
CD11blowCADO48Alow were immunosuppressive. On-
going studies are evaluating the functional abilities and
signaling pathways involved in the development of ca-
nine MDSCs using our in vitro MDSCs model.
While significant differences in R1 and P1 were found
when tumor-bearing patients were grouped according
to tumor type (Table 3), it was somewhat surprising that
P4 differences were not significant. The most likely rea-
son for this is that subcategorization decreased the num-
ber of patients in each tumor type category which then
resulted in a lack of statitistical significance. An add-
itional prospective study with recruitment of more
patients according to individual tumor types would likely
address this possibility. One interesting aspect of our
study is the mixed population of tumors evaluated. In the
human literature, the predominance of tumors shown to
upregulate MDSCs are carcinomas, including those
arising from the pancreas, colon and lung [32-34]. Unlike
in humans, sarcomas are a relatively common tumor type
seen in veterinary species and studies investigating
MDSC populations in humans have found this cell type
primarily in various carcinomas and melanoma [35]. The
fact that MDSCs were upregulated in our tumor-bearing
population, regardless of tumor type suggests that
common mechanisms exist between sarcomas and car-
cinomas for the induction of MDSCs in the caninepopulation. Interestingly, melanomas appear to upregulate
MDSCs regardless of species (Table 3) [32-35]. Studies of
MDSCs in dogs may be useful at dissecting the potential
mechanisms by which carcinomas, sarcomas or melano-
mas differentially regulate MDSCs levels and why these
may differ between species. Additionally, specific tumor
types may uniquely upregulate specific MDSC subsets
such as seen with the predominance of CD15+ MDSC or
lineage negative MDSCs in patients with glioblastoma
[36]. At present, a detailed evaluated of canine MDSC
subpopulations is not feasible but our data suggest that
CADO48A may be a useful antibody for such distinctions.
CD11b+CD14-MHCII- cells have been identified as
MDSCs in the peripheral blood of dogs (Goulart 2012)
in both solitary and metastatic cancer and these cells
were able to suppress T cell proliferation similar to what
we found with CD11blowCADO48Alow cells [115]. Our
studies demonstrate that CADO48A is a useful marker
to identify MDSCs in dogs and it is not known whether
CD11blowCADO48Alow and CD11b+CD14-MHCII- rep-
resent two distinct MDSC populations (e.g. granulocytic
and monocytic, respectively) and, if so, whether these
two populations have distinct functional profiles. The
identification of MDSC subpopulations is likely to be
useful for diagnostic and prognostic purposes but the
characterization of these populations in canines is only
in its infancy. Additional markers, such as S100A9, have
been described to identify monocytic MDSCs in humans
with colon cancer and cross-reacting S100A9 proteins are
available [33]. Ongoing studies evaluating various MDSC
markers are needed to determine the phenotype and func-
tion of specific MDSC subpopulations (e.g. monocytic
and granulocytic) in dogs. Utilization of both canine
patients and an in vitro model system as we provide
here are likely to provide important data on MDSC
phenotype and function and facilitate translational appli-
cations between canine and human MDSC studies.
Conclusion
This study identified canine specific markers that can be
used to identify specific myeloid cell populations within
clinical samples from dogs. Our data demonstrate that
canine-specific antibodies can be used to identify a spe-
cific population of myeloid cells (CD11blowCADO48Alow)
which are increased in tumor-bearing canine patients and
that purified CD11blowCADO48Alow cells suppressed the
proliferation of canine lymphocytes. This work provides a
foundation for future investigations of MDSC levels which
may serve as a prognostic indicator in canine patients
and help guide translational research approaches for
cancer immunotherapy in human and veterinary cancer
patients. The field of immunotherapy, both in man and
in the veterinary field, is in a state of constant discovery.
The ability to identify and monitor MDSC levels in the
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new therapies in both man and his best friend.
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